Genovis Evaluates New Technology for Early Diagnosis of Cardiovascular Disease
8/14/2013 8:35:05 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Genovis signed an agreement with Repiratorius to test and evaluate RESP-3000 as
a new biomarker for early diagnosis of cardiovascular disease using PET-Imaging.
Genovis is coordinating the work, but GeccoDots AB, Genovis’ wholly owned
subsidiary, will conduct the final evaluation. Work will begin immediately and
the evaluation is expected to be completed in late 2013 or early 2014.
The agreement includes the option for Genovis to acquire technology and patents
relating to RESP-3000 in preclinical applications and Genovis intends to
initiate negotiations for an acquisition if the tests show favorable results.
Help employers find you! Check out all the jobs and post your resume.
comments powered by